Search results for "wt"

showing 10 items of 5424 documents

Is ABA involved in tolerance responses to salinity by affecting cytoplasm ion homeostasis in rice cell lines?

2012

Abstract The ability of plant cells to maintain cytoplasm ion homeostasis under saline stress is among the main mechanisms involved in salt tolerance. To cope with excess Na + , cells extrude it from the cytoplasm, which requires expenditure of metabolic energy, provided by H + gradients generated by membrane-bound H + -pumps. ABA is well-known to be involved in physiological processes elicited or enhanced by stresses causing cell dehydration. In this work we studied the possible implication of this plant hormone in the control of salt-induced cellular mechanisms conducting to Na + extrusion from the cytoplasm. We used rice ( Oryza sativa L.) cell lines selected for their different toleranc…

Sodium-Hydrogen ExchangersPhysiologyAntiporterPlant ScienceVacuoleBiologychemistry.chemical_compoundPlant Growth RegulatorsPlant CellsGeneticsAbscisic acidPlant ProteinsCell MembraneSodiumfungiProton-Motive Forcefood and beveragesOryzaWater-Electrolyte BalancePlant cellAntiportersIon homeostasisBiochemistrychemistryCytoplasmBiophysicsHomeostasisAbscisic AcidPlant Physiology and Biochemistry
researchProduct

Supercritical hydrothermal synthesis of ZnO nanopowders beyond the critical point : understanding of nucleation and growth steps

2014

The supercritical hydrothermal synthesis of nanopowders (especially metal oxide) has been widely studied. To the best of our knowledge, no nanoparticle formation mechanism has been published yet. In this prospect, this study is dedicated to the understanding of metal oxide nanoparticle nucleation and growth mechanisms. For this purpose, zinc oxide is used as a model material. First, the influence of synthesis operating conditions such as pressure, temperature, pH, precursor concentrations and solution flow rates on particle morphological properties (size, particle size distribution or morphologies) has been investigated. Hence, two approaches have simultaneously been carried out. The first …

SolubilitéMécanismeNanoparticulesFormationGrowth[PHYS.PHYS.PHYS-CHEM-PH] Physics [physics]/Physics [physics]/Chemical Physics [physics.chem-ph]SolubilityZnOMechanismsNucleationNanoparticlesSCWEau supercritiqueNucléationCFDCroissanceSupercritical water
researchProduct

Cardiovascular Damage Induced by Anti-VEGF Therapy

2018

Vascular endothelial growth factor (VEGF) plays an important role in maintaining the regular homeostasis of vascular walls. VEGF binds its receptor (VEGFR) promoting the regular survival and function of endothelial cells. Anti-VEGF and anti-VEGFR drugs inhibit the action of VEGF and VEGFR. These drugs can cause cardiovascular toxic effects such as arterial hypertension, thromboembolism, myocardial ischemia and heart failure. The monoclonal antibody bevacizumab and tyrosine kinase inhibitors (sorafenib, sunitinib, pazopanib, regorafenib, axitinib, cabozantinib, ponatinib) are the main inhibitors of VEGF, VEGFR and other tyrosine kinases. In this chapter we will illustrate the cardiovascular …

SorafenibCabozantinibSunitinibbusiness.industryAxitinibVascular endothelial growth factorPazopanibchemistry.chemical_compoundchemistryRegorafenibmedicineCancer researchbusinessTyrosine kinasemedicine.drug
researchProduct

Molecular mechanisms of sorafenib action in liver cancer cells.

2012

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib evolves, there is increasing interest in defining the mechanisms underlying its anti-tumor activity. Considering that this specific inhibitor could target unexpected molecules depending on the biologic context, a precise understanding of its mechanism of action could be critical to maximize its treatment efficacy, while minimizing adverse effects. Two human HCC cell lines (HepG2 and Huh7), carrying different biological and genetic characteristics, were used in this study to examine the intracellular events leading …

SorafenibDNA ReplicationNiacinamideCarcinoma HepatocellularDNA RepairTranscription GeneticAngiogenesisCell SurvivalPyridinesApoptosisPharmacologyBiologysorafenib HCC mini-chromosome maintenance genes Dickkopf1 Harakiri Acheron/LARP6 YAP1 cell cycle microarray global gene expression analysisCell Line TumormedicineCell AdhesionHumansneoplasmsMolecular BiologyProtein Kinase InhibitorsCell ProliferationYAP1Neovascularization PathologicCell growthGene Expression ProfilingPhenylurea CompoundsBenzenesulfonatesCell CycleLiver NeoplasmsBiological TransportCell BiologyCell cycleSorafenibmedicine.diseasedigestive system diseasesMechanism of actionHepatocellular carcinomaProtein Biosynthesismedicine.symptomMitogen-Activated Protein KinasesLiver cancerDevelopmental Biologymedicine.drugSignal Transduction
researchProduct

BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.

2013

Abstract: Introduction: Several new targeted agents with anti-angiogenic properties have been developed recently, including vandetanib, sunitinib, sorafenib, bevacizumab and others. Tumor development, progression, metastasis are strongly linked to angiogenesis. Targeted agents like bevacizumab, a monoclonal antibody which targets VEGF, have been fully developed in several solid tumors. These new agents strongly advocate that targeting angiogenesis is one of the best approaches for cancer therapy. Areas covered: Those agents that target additional pro-angiogenic intracellular signaling pathways beyond VEGF signaling have also the potential to contribute to anticancer therapies. The authors p…

SorafenibIndolesLung NeoplasmsBevacizumabSettore MED/06 - Oncologia MedicaAngiogenesis InhibitorsPharmacologyVandetanibMetastasischemistry.chemical_compoundCarcinoma Non-Small-Cell LungmedicineAnimalsHumansPharmacology (medical)Lung cancerProtein Kinase InhibitorsPharmacologyNeovascularization Pathologicbusiness.industrySunitinibPharmacology. Therapyanti-angiogenesis BIBF 1120 nintedanib non-small cell lung cancer vascular endothelial growth factorGeneral MedicineProtein-Tyrosine Kinasesmedicine.diseaseVascular endothelial growth factorchemistryCancer researchNintedanibbusinessmedicine.drugExpert opinion on investigational drugs
researchProduct

Sorafenib (SFB) treated elderly patients (E) with hepatocellular carcinoma (HCC): Chromogranine A (CGA) plus vascular endothelial growth factor (VEGF…

2012

e14676 Background: HCC accounts for approximately 90% of all primary liver cancers, and is the fifth most common cancer in the world and prognosis is so far very poor,particularly in E patients.Between all tentative of treatment till know SFB seems to be the most promising drug in patients with advanced or metastatic HCC.Aim of the study is to investigate if SFB is efficient and safe also in E HCC patients despite the comorbidities and other problems. Objectives: To investigate if CgA and VEGF work as predicting factors of Sorafenib treatment outcomes. Methods: 51 patients, mean age 68,9 (65-85) with HCC were enrolled . Serum CgA, VEGF and αFP were evaluated at baseline and after end of tr…

SorafenibOncologyCancer ResearchPathologymedicine.medical_specialtybiologybusiness.industryVEGF receptorsTreatment outcomeCancermedicine.diseaseVascular endothelial growth factorchemistry.chemical_compoundOncologychemistryGeriatric oncologyHepatocellular carcinomaInternal medicinemedicinebiology.proteinbusinessgeriatric oncologymedicine.drug
researchProduct

The role of targeted therapy for gastrointestinal tumors

2014

Abstract: Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinic…

SorafenibOncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyReceptor ErbB-2Hepatocellular carcinomaSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsNeuroendocrine tumorsTargeted therapyTargeted therapychemistry.chemical_compoundNeuroendocrine tumorTrastuzumabInternal medicineRegorafenibmedicineHumansGastrointestinal tumorsMolecular Targeted TherapyProtein Kinase InhibitorsGastrointestinal NeoplasmsEverolimusHepatologySunitinibbusiness.industryColorectal cancer; Gastric cancer; Gastrointestinal tumors; Hepatocellular carcinoma; Neuroendocrine tumors; Targeted therapy; Hepatology; GastroenterologyGastrointestinal tumorGastroenterologyCancermedicine.diseaseColorectal cancerErbB ReceptorsReceptors Vascular Endothelial Growth FactorchemistryHuman medicineNeuroendocrine tumorsbusinessGastric cancermedicine.drug
researchProduct

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

2015

Abstract: Introduction: Angiogenesis is fundamental for tumor development and progression. Hence, anti-angiogenic drugs have been developed to target VEGF and its receptors (VEGFRs). Several tyrosine kinase inhibitors (TKIs) have been developed over the years and others are still under investigation, each anti-VEGFR TKI showing a different cardiotoxic profile. Knowledge of the cardiac side-effects of each drug and the magnitude of their expression and frequency can lead to a specific approach. Areas covered: This work reviews the mechanism of action of anti-VEGFR TKIs and the pathophysiological mechanisms leading to cardiotoxicity, followed by close examination of the most important drugs i…

SorafenibOncologymedicine.medical_specialtymedicine.drug_classSettore MED/06 - Oncologia MedicaAntineoplastic AgentsPharmacologyVandetanibModels BiologicalTyrosine-kinase inhibitorPazopanibchemistry.chemical_compoundInternal medicineRegorafenibNeoplasmsmedicineHumansPharmacology (medical)Molecular Targeted TherapyProtein Kinase Inhibitorstyrosine kinase inhibitor cardiac toxicityNeovascularization PathologicSunitinibbusiness.industryPharmacology. TherapyCancerHeartGeneral MedicineDrugs InvestigationalProtein-Tyrosine Kinasesmedicine.diseaseAxitinibReceptors Vascular Endothelial Growth FactorchemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Suffix array and Lyndon factorization of a text

2014

Abstract The main goal of this paper is to highlight the relationship between the suffix array of a text and its Lyndon factorization. It is proved in [15] that one can obtain the Lyndon factorization of a text from its suffix array. Conversely, here we show a new method for constructing the suffix array of a text that takes advantage of its Lyndon factorization. The surprising consequence of our results is that, in order to construct the suffix array, the local suffixes inside each Lyndon factor can be separately processed, allowing different implementative scenarios, such as online, external and internal memory, or parallel implementations. Based on our results, the algorithm that we prop…

Sorting suffixes; BWT; Suffix array; Lyndon word; Lyndon factorizationCompressed suffix arraySettore INF/01 - InformaticaSorting suffixesGeneralized suffix treeSuffix arrayOrder (ring theory)Construct (python library)Lyndon wordSorting suffixeTheoretical Computer Sciencelaw.inventionBWTLyndon factorizationComputational Theory and MathematicsFactorizationlawSuffix arrayFactor (programming language)Internal memoryDiscrete Mathematics and CombinatoricsArithmeticcomputerMathematicscomputer.programming_languageJournal of Discrete Algorithms
researchProduct

Contrasting age-specific recruitment and survival at different spatial scales: A case study with the European storm petrel

2009

Evolutionary studies on optimal decisions or conservation guidelines are often derived by generalising patterns from a single population, while inter-population variability in life-history traits is seldom considered. We investigated here how survival and recruitment probabilities changed with age at different geographical scales using the encounter histories of 5523 European storm petrels from three Mediterranean colonies, and also how our estimates of these parameters might be expected to affect population growth rates using population matrix models. We recorded similar patterns among colonies, but also important biological differences. Local survival, recruitment and breeding success inc…

Southern EuropeConservation managementSurvivalPopulationSettore BIO/05 - ZoologiaVulnerabilityPredationAge structurePredationLife history theoryBenidormPopulation modelingbiology.animalLife history theoryPopulation growthPopulation growthMortalityeducationEcology Evolution Behavior and SystematicsSpecies conservationeducation.field_of_studybiologyReproductive successGrowth rateEcologySpatial analysisReproductive successSeabirdSpatial heterogeneitySpainHydrobates pelagicus Recruitment Mediterranean populationsLife history traitSeabirdVital ratesComunidad ValencianaRecruitment (population dynamics)
researchProduct